Literature DB >> 20861454

Pain in Guillain-Barre syndrome: a long-term follow-up study.

L Ruts1, J Drenthen, J L M Jongen, W C J Hop, G H Visser, B C Jacobs, P A van Doorn.   

Abstract

BACKGROUND: Pain in Guillain-Barré syndrome (GBS) may be pronounced and is often overlooked.
OBJECTIVES: To obtain detailed information about pain in GBS and its clinical variants.
METHODS: This was a prospective cohort study in 156 patients with GBS (including 18 patients with Miller Fisher syndrome [MFS]). We assessed the location, type, and intensity of pain using questionnaires at standard time points during a 1-year follow-up. Pain data were compared to other clinical features and serology.
RESULTS: Pain was reported in the 2 weeks preceding weakness in 36% of patients, 66% reported pain in the acute phase (first 3 weeks after inclusion), and 38% reported pain after 1 year. In the majority of patients, the intensity of pain was moderate to severe. Longitudinal analysis showed high mean pain intensity scores during the entire follow-up. Pain occurred in the whole spectrum of GBS. The mean pain intensity was predominantly high in patients with GBS (non-MFS), patients with sensory disturbances, and severely affected patients. Only during later stages of disease, severity of weakness and disability were significantly correlated with intensity of pain.
CONCLUSIONS: Pain is a common and often severe symptom in the whole spectrum of GBS (including MFS, mildly affected, and pure motor patients). As it frequently occurs as the first symptom, but may even last for at least 1 year, pain in GBS requires full attention. It is likely that sensory nerve fiber involvement results in more severe pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861454     DOI: 10.1212/WNL.0b013e3181f88345

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

Review 2.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 3.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

Review 4.  Pharmacological treatment for pain in Guillain-Barré syndrome.

Authors:  Jia Liu; Lu-Ning Wang; Ewan D McNicol
Journal:  Cochrane Database Syst Rev       Date:  2015-04-09

5.  A rare case of Guillain-Barré syndrome presenting with abdominal pain.

Authors:  G Michas; A Nikolopoulou; E Varytimiadi; N Xydia
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

Review 6.  Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.

Authors:  Pallavi Asthana; Joaquim Si Long Vong; Gajendra Kumar; Raymond Chuen-Chung Chang; Gang Zhang; Kazim A Sheikh; Chi Him Eddie Ma
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

Review 7.  Headache and Pain in Guillain-Barré Syndrome.

Authors:  Constantine Farmakidis; Seniha Inan; Mark Milstein; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2015-08

8.  Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.

Authors:  Dae Young Jung; Keun-Tae Cho; Seung Chul Lee
Journal:  J Korean Neurosurg Soc       Date:  2013-04-30

Review 9.  Pain management in neurocritical care.

Authors:  Axel Petzold; Armand Girbes
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

10.  Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study.

Authors:  Valeria Prada; Federico Massa; Alexander Salerno; Davide Fregosi; Alessandro Beronio; Carlo Serrati; Antonio Mannironi; Giovanni Mancardi; Angelo Schenone; Luana Benedetti
Journal:  Neurol Sci       Date:  2019-10-04       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.